Legend Biotech Corp. reported a robust performance for Q4 2024, driven by a significant increase in CARVICTI sales. The company achieved net sales of $334 million for CARVICTI, marking a 110% ...

Legend Power Systems reported its financial results for the third quarter of 2025, showing a significant drop in revenue and gross margin compared to the previous year. Revenue was $385,000, down from ...

Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a ...

Legend Biotech Corp (LEGN) reported its third-quarter earnings for 2025, revealing a mixed performance that fell short of market expectations. The company posted an earnings per share (EPS) of -$0.05, ...

Legend Biotech Corp (LEGN) reported its second-quarter earnings for 2025, revealing a significant increase in revenue but a larger-than-expected loss per share. The company’s revenue reached 255.06 ...

Earnings call Legend Power Systems reported Q1 revenue of CAD 82,000, up sharply from CAD 2,000 YoY, with gross margin improving to 15% from negative levels. Management emphasized strong backlog, cost ...

Good day, and welcome to Legend Biotech Reports Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and ...

Legend Biotech Corporation beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.56. Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Legend Biotech ...